2026-03-10 - TMO - Thermo Fisher Scientific Deep Dive

Article published Mar 10, 2026. Prices below use latest available snapshots.

TMO Price Structure

Loading chart…

Loading timeframes…

Conviction: Medium-High Status: Buy — RSI 38.4, price $509.97, in entry zone, consolidating near SMA

Quick Snapshot

Signal	Reading
Overall	🟡 RSI 38.4 (computed) — approaching neutral from oversold. Price $509.97, +1.6% today, +0.3% 7D, -5.5% 30D. SMA20 ~$514.21 — price -0.8% below SMA.
Moat	Wide (lab equipment, reagents, instruments monopoly)
Key insight	TMO continues steady consolidation. Price essentially flat vs 03/03 ($507.81, +0.4%). RSI improved from 31.2 to 38.4 — the recovery continues its step pattern (5.5 → 19.2 → 32.2 → 31.2 → 38.4). SMA gap narrowed dramatically from -3.2% to just -0.8%. Price is converging with SMA. Still in entry zone ($490-$525). Buy maintained.

Action Matrix

Action	Level	Why
Current	✅ Buy	RSI 38 recovering, in entry zone, SMA gap nearly closed. Wide moat.
Entry Zone	$490 - $525	Current $509.97 — IN ZONE
Stop-Loss	$440 (-14%)	Below multi-year support
Target	$650 (+27%)	Recovery toward prior levels

Extended analysis

Price Data

Stock	Price	1D	7D	30D	3M	52wkHi	RSI	Status	Action
TMO	$509.97	+1.6%	+0.3%	-5.5%	—	-7.4%	38	🟡 Approaching Neutral	✅ Buy

Price vs Last Deep Dive (03/03)

Metric	03/03	03/10	Change
Price	$507.81	$509.97	+$2.16 (+0.4%)
RSI	31.2	38.4	+7.2 (recovery continues)
SMA20	$524.67	~$514.21	-$10.46 (SMA continuing to decline)
vs SMA	-3.2%	-0.8%	Gap nearly closed
30D	-10.9%	-5.5%	Continued improvement

Update from 03/03: TMO continues its steady recovery pattern. Price ticked up slightly to $509.97 (+0.4%) while RSI improved meaningfully from 31.2 to 38.4 (+7.2). The SMA has continued its sharp decline ($524.67 → $514.21), narrowing the gap to just -0.8%. At this pace, price should cross above SMA within the next week. The stepwise RSI recovery (5.5 → 19 → 32 → 31 → 38) is textbook base-building. 30D improved from -10.9% to -5.5%. Buy maintained — still in entry zone and thesis unchanged.

Company Overview

One-Liner

Thermo Fisher Scientific is the world's largest life sciences company, providing analytical instruments, equipment, reagents, and services to every lab and pharma company globally.

Business Model

Question	Answer
What they sell	Lab instruments, scientific reagents, specialty chemicals, CRO/bioprocessing services
Who pays	Pharma/biotech (50%), hospitals/diagnostic labs (20%), academic/government (20%), industrial (10%)
Revenue model	Equipment (one-time), consumables/reagents (recurring), service contracts, bioproduction
How sticky	Very high — instruments require calibration, reagents qualified per protocol

Key Segments

Segment	Revenue %	Growth	Notes
Life Sciences Solutions	~35%	+8% YoY	Reagents, bioprocessing, gene editing
Analytical Instruments	~25%	+6% YoY	Mass spec, chromatography
Specialty Diagnostics	~20%	+5% YoY	Clinical diagnostics
Lab Products & Biopharma Services	~20%	+4% YoY	Lab supplies, CRO

Competitive Analysis

Moat Type	Present?	Evidence
Switching costs	🟢	Scientific protocols lock in specific instruments/reagents
Intangible assets	🟢	Thermo, Fisher Scientific brand trust in research
Cost advantages	🟢	$45B+ revenue = unmatched supply chain scale
Efficient scale	🟢	Only company covering full lab workflow

Moat Width: Wide Moat Trend: Stable

Bull Case

Essential infrastructure — Every lab needs TMO products. No substitution.
Bioproduction secular tailwind — mRNA, cell therapy, gene editing require TMO equipment.
RSI recovery 5.5 → 38 (step pattern) — Steady, healthy recovery continuing.
SMA gap nearly closed — Convergence imminent.
Picks-and-shovels for pharma AI — AI drug discovery increases instrument demand.

Bear Case

Pharma R&D budget cuts — Largest segment cutting spending.
Insider selling $323.3M — Among highest in coverage.
China exposure ~15% — Geopolitical risk.
CRO competition — PPD segment vs IQVIA.

Thesis Killers

Top pharma companies announce R&D cuts >10%
China bans TMO instrument imports
Bioproduction demand collapses

Entry Strategy

Level	Price	Notes
Support 1	$490	Entry zone floor
Support 2	$440	Stop-loss
Resistance 1	$514	SMA20 — about to reclaim
Resistance 2	$550	In-window 52wk high

Entry Approach

Strategy	Details
Entry zone	$490 - $525
Starter	2% of portfolio
Add	RSI breaks above 45 with price above SMA
Full	RSI > 50 + SMA convergence

Research Log

Date	Update
2026-02-16	Created. RSI 5.5 extreme. $504.82. Insider selling $323.3M. Action: Buy.
2026-02-22	Price $510.93 (+1.2%). RSI 19.2 (+13.7 pts). Buy maintained.
2026-02-26	Price $515.03 (+0.8%). RSI 32.2. SMA gap -3.8%. Near entry zone top. Buy.
2026-03-03	Price $507.81 (-1.4%). RSI 31.2. Consolidation. SMA gap -3.2%. Buy.
2026-03-10	Price $509.97 (+0.4%). RSI 38.4 (computed). SMA gap -0.8% (nearly closed). 30D -5.5%. Recovery continues. Buy.

The Gold

Key Discoveries

Discovery	Implication
RSI 5.5 → 19 → 32 → 31 → 38 = textbook step recovery	Base-building pattern continues; SMA crossover imminent
SMA declined from $556 → $514: converging with price	Price may cross SMA without needing to rally significantly
30D: -17.8% → -10.9% → -5.5%	Steady improvement; will be positive within 1-2 weeks
SMA gap: -13% → -3.8% → -3.2% → -0.8%	Convergence nearly complete

Open Questions

What drove the RSI 5.5 extreme? Forced selling?
Are insider sales ($323.3M) on scheduled plans?
What is TMO's China revenue exposure?
When does TMO report next earnings?

Mistakes (Don't Repeat)

Mistake	Lesson
None yet	Stepwise recovery confirms patience is correct approach

Sources

Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.